LYPHF (Luye Pharma Group) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYPHF Luye Pharma Group Ltd LYPHF
50 GF Score
Price $0.32
GF Value $0.45
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Luye Pharma Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LYPHF vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Luye Pharma Group Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Margin of Safety % (DCF Earnings Based) falls into.


LYPHF
50GF Score
Luye Pharma Group Ltd LYPHF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Luye Pharma Group (LYPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of $0.32 is trading 29.6% below its estimated GF Value™ of $0.45. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for LYPHF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.45 vs. price of $0.32 (29.6% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the LYPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges 02186:Hong KongLUP:Germany
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
50GF Score

Get the complete analysis for LYPHF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.45
GF Value